Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5744-5756

  Martin Oliva, David ^a,b   Aguilar Quesada, Rocío ^a   O'Valle, Francisco ^c   Muñoz Gámez, Jose Antonio ^a,c   Martínez Romero, Rubén ^a   García Del Moral, Raimundo ^c   Ruiz De Almodóvar, José Mariano ^c   Villuendas, Raquel ^d   Piris, Miguel Angel ^d   Oliver, F Javier ^a,e  

^a CSIC   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 5 [4 (1 PIPERIDINYL)BUTOXYL] 1(2H) ISOQUINOLINE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA BINDING; GENE DELETION; GENE EXPRESSION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CARCINOGENESIS; SKIN INFLAMMATION; TUMOR PROMOTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOQUINOLINES; MICE; MICE, INBRED C57BL; NF-KAPPA B; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1;

EID: 33745288540     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3050     Document Type: Article

References (42)

1. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
2. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9 Suppl 5:10-7.
3. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000;460:1-15.
4. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82.
5. Masutani M, Nakagama H, Sugimura T. Poly(ADP-ribose) and carcinogenesis. Genes Chromosomes Cancer 2003;38:339-48.
6. Martin-Oliva D, O'Valle F, Munoz-Gamez JA, et al. Crosstalk between PARP-1 and NF-κB modulates the promotion of skin neoplasia. Oncogene 2004;23:5275-83.
7. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 1999;274:24147-52.
8. Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004;64:5527-34.
9. Van Gelder RN, von Zastrow ME, Yool A, et al. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
10. Eberwine J. Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA. BioTechniques 1996;20:584-91.
11. Tamames J, Clark D, Herrero J, et al. Bioinformatics methods for the analysis of expression arrays: data clustering and information extraction. J Biotechnol 2002;98:269-83.
12. Burbach GJ, Dehn D, Del Turco D, Deller T. Quantification of layer-specific gene expression in the hippocampus: effective use of laser microdissection in combination with quantitative RT-PCR. J Neurosci Methods 2003;131:83-91.
13. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005;386:119-25.
14. Li JJ, Dong Z, Dawson MI, Colburn NH. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res 1996;56:483-9.
15. Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989;244:566-9.
16. Oliver FJ, Menissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J 1999;18:4446-54.
17. Hassa PO, Buerki C, Lombardi C, Imhof R, Hottiger MO. Transcriptional coactivation of nuclear factor-κB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem 2003;278:45145-53.
18. Andreone TL, O'Connor M, Denenberg A, Hake PW, Zingarelli B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J Immunol 2003;170:2113-20.
19. Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. The enzymatic and DNA binding activity of PARP-1 are not required for NF-κ B coactivator function. J Biol Chem 2001;276:45588-97.
20. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993;268:21513-8.
21. Gebhardt C, Breitenbach U, Tuckermann JP, et al. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 2002;21:4266-76.
22. Vandal K, Rouleau P, Boivin A, et al. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide. J Immunol 2003;171:2602-9.
23. Alvarez-Tejado M, Alfranca A, Aragones J, et al. Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 2002;277:13508-17.
24. Marks F, Furstenberger G. The conversion stage of skin carcinogenesis. Carcinogenesis 1990;11:2085-92.
25. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249-68.
26. Kannan P, Yu Y, Wankhade S, Tainsky MA. PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation. Nucleic Acids Res 1999;27:866-74.
27. Cervellera MN, Sala A. Poly(ADP-ribose) polymerase is a B-MYB coactivator. J Biol Chem 2000;275:10692-6.
28. Nie J, Sakamoto S, Song D, Qu Z, Ota K, Taniguchi T. Interaction of Oct-1 and automodification domain of poly(ADP-ribose) synthetase. FEBS Lett 1998;424:27-32.
29. Oei SL, Griesenbeck J, Schweiger M, et al. Interaction of the transcription factor YY1 with human poly(ADP-ribosyl) transferase. Biochem Biophys Res Commun 1997;240:108-11.
30. Butler AJ, Ordahl CP. Poly(ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription. Mol Cell Biol 1999;19:296-306.
31. Wesierska-Gadek J, Schmid G. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell Mol Biol Lett 2001;6:117-40.
32. Amstad PA, Krupitza G, Cerutti PA. Mechanism of c-fos induction by active oxygen. Cancer Res 1992;52:3952-60.
33. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
34. Schlingemann J, Hess J, Wrobel G, et al. Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer 2003;104:699-708.
35. Yasumoto H, Matsubara A, Mutaguchi K, Usui T, McKeehan WL. Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 2004;61:236-42.
36. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004;68:1061-9.
37. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998;78:1269-77.
38. Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002;99:2241-4.
39. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
40. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
41. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
42. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.